
ANPCY
Healthcare · Diagnostics & Research · $25.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 9, 2025 | Time not confirmed | — | -0.03 | — |
| Jun 7, 2025 | Time not confirmed | — | -0.02 | — |
| Sep 26, 2024 | Time not confirmed | — | -0.03 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.02 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.02 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.01 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.01 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.02 | — |
| Apr 30, 2019 | Time not confirmed | 0.00 | -0.02 | — |
| Jan 31, 2019 | Time not confirmed | 0.00 | -0.02 | — |
| Apr 30, 2018 | Time not confirmed | 0.00 | -0.02 | — |
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and…
| Jan 31, 2018 |
| Time not confirmed |
| 0.00 |
| -0.03 |
| — |